Development of LC-MS/MS-based receptor occupancy tracers and positron emission tomography radioligands for the nociceptin/orphanin FQ (NOP) receptor

Journal of Medicinal Chemistry

Volumn 55, Issue 11, 2012, Pages 4955-4967

  Pedregal, Concepción ^a   Joshi, Elizabeth M ^b   Toledo, Miguel A ^a   Lafuente, Celia ^a   Diaz, Nuria ^a   Martinez Grau, Maria A ^a   Jiménez, Alma ^a   Benito, Ana ^a   Navarro, Antonio ^b   Chen, Zhaogen ^b   Mudra, Daniel R ^b   Kahl, Steven D ^b   Rash, Karen S ^b   Statnick, Michael A ^b   Barth, Vanessa N ^b  

^a ELI LILLY AND COMPANY   (Spain)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOCICEPTIN RECEPTOR; NOCICEPTIN RECEPTOR ANTAGONIST OCCUPANCY TRACER; RADIOLIGAND; RECEPTOR BLOCKING AGENT; TRACER; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BINDING; DRUG UPTAKE; EXPERIMENTAL MONKEY; HYPOTHALAMUS; IN VIVO STUDY; LIPOPHILICITY; LIQUID CHROMATOGRAPHY; MALE; MENTAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RAT; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; TANDEM MASS SPECTROMETRY; THALAMUS;

ANIMALS; BRAIN; CARBON RADIOISOTOPES; CHO CELLS; CHROMATOGRAPHY, LIQUID; CRICETINAE; CRICETULUS; HEK293 CELLS; HUMANS; MACACA; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID; SPIRO COMPOUNDS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TANDEM MASS SPECTROMETRY; THIOPHENES;

EID: 84862288474     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201629q     Document Type: Article

References (34)

1. Meunier, J. C.; Mollereau, C.; Toll, L.; Suaudeau, C.; Moisand, C.; Alvinerie, P.; Butour, J. L.; Guillemot, J. C.; Ferrara, P.; Monsarrat, B.; Mazarguil, H; Vassart, G.; Parmentier, M.; Costentin, J. Isolation and structure of the endogenous agonist of opioid-like ORL 1 receptor Nature 1995, 377, 532-535
2. Reinschied, R. K.; Nothacker, H.-P.; Bourson, A.; Ardati, A.; Henningsen, R. A.; Bunzow, J. R.; Grandy, D. K.; Langen, H; Monsma, F, Jr.; Civelli, O. Orphanin FQ: a neuropeptide that activates an opioid-like G-protein coupled receptor Science 1995, 270, 792-794
3. Mogli, J. S.; Pasternak, G. W. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family Pharmacol. Rev. 2001, 53, 381-415
4. Lambert, D. G. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential Nature Rev. Drug Discovery 2008, 7, 694-710
5. Murphy, N. P. The nociceptin/orphamin FQ system as a target for treating alcoholism CNS Neurol. Disord.: Drug Targets 2010, 9, 87-93
6. Largent-Milnes, T. M.; Vanderah, T. W. Recently patented and promising ORL-1 ligands: where have we been and where are we going? Expert Opin. Ther. Pat. 2010, 20, 291-305
7. Phelps, M. E. Positron emission tomography provides molecular imaging of biological processes Proc. Natl. Acad. Sci., U.S.A. 2000, 97, 9226-9233
8. Wong, D. F.; Gründer, G.; Brašić, J. R. Brain imaging research: does the science serve clinical practice? Int. Rev. Ps ychiatry 2007, 19, 541-558
9. Lee, C. M.; Farde, L. Using positron emission tomography to facilitate CNS drug development Trends Pharmocol. Sci. 2006, 27, 310-316
10. Patel, S.; Gibson, R. In vivo site-directed radiotracers: a mini-review Nucl. Med. Biol. 2008, 35, 805-815
11. Pike, V. W. PET Radiotracers: crossing the blood-brain barrier and surviving metabolism Trends Pharmocol. Sci. 2009, 30, 431-440
12. Chernet, E.; Martin, L. J.; Li, D.; Need, A. B.; Barth, V. N.; Rash, K. S.; Phebus, L. A. Use of LC/MS to assess brain tracer distribution in preclinical in vivo receptor occupancy studies: Dopamine D2, serotonin 2A and NK-1 receptors as examples Life Sci. 2005, 78, 340-346
13. Barth, V. N.; Chernet, E.; Martin, L. J.; Rash, K. S.; Morin, M.; Phebus, L. A. Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or unlabeled raclopride tracer Life Sci. 2006, 78, 3007-3012
14. Pike, V. W.; Rash, K. S.; Chen, Z.; Pedregal, C.; Statnick, M. A.; Kimura, Y.; Hong, J.; Zoghbi, S. S.; Fujita, M.; Toledo, M. A.; Diaz, N.; Gackenheimer, S. L.; Tauscher, J. T.; Barth, V. N.; Innis, R. B. Synthesis and Evaluation of Radioligands for Imaging Brain Nociceptin/Orphanin FQ Peptide (NOP) Receptors with Positron Emission Tomography J. Med. Chem. 2011, 54, 2687-2700
15. 11C-NOP-1A, a Promising PET Radioligand for Nociceptin/Orphanin FQ Peptide Receptors J. Nucl. Med. 2011, 52, 1638-1645
16. 14Tyr)-orphanin FQ binding J. Comp. Neurol. 1999, 412, 563-605
17. 3H]nociceptin binding sites in the rat brain Brain Res. 2000, 880, 11-16
18. 10]orphanin FQ/nociceptin(1-11) binding sites in rat brain J. Comp. Neurol. 2000, 423, 319-329
19. 3H]Ac-RYYRIK-ol Neurochem. Int. 2009, 55, 458-466
20. 125I[Tyr14] nociceptin/orphanin FQ binding sites in macaque primate CNS Neuroscience 2003, 118, 513-523
21. Donohue, S. R.; Krushinski, J. H.; Pike, V. W.; Chernet, E.; Phebus, L.; Chesterfield, A. K.; Ferder, C. C.; Halldin, C.; Schaus, J. M. Synthesis, Ex Vivo Evaluation, and Radiolabeling of Potent 1,5-Diphenylpyrrolidin-2-one Cannabinoid Sutype-1 Receptor Ligands as Candidates for In Vivo Imaging J. Med. Chem. 2008, 51, 5833-5842
22. Mitch, C. H.; Quimby, S. J.; Diaz, N.; Pedregal, C.; G. de la Torre, M.; Jiménez, A.; Shi, Q.; Canada, E. J.; Kahl, S. D.; Statnick, M. A.; McKinzie, D. L.; Benesh, D. R.; Rash, K. S.; Barth, V. N. Discovery of Aminobenzyloxyarylamides as κ Opioid Receptor Selective Antagonists: Application to Preclinical Development of a κ Opioid Receptor Antagonist Receptor Occupancy Tracer J. Med. Chem. 2011, 54, 8000-8012
23. 11C]methyl-Ro-64-6198 as an ORL1 receptor imaging agent Nucl. Med. Biol. 2001, 28, 941-947
24. 11C]ethyl-1,3-dihydro-2 H -benzimidazol-2-one as a brain ORL1 receptor imaging agent for positron emission tomography Nucl. Med. Biol. 2003, 30, 51-59
25. Teshima, K.; Minoguchi, M. Remedy for sleep disturbance. Patent WO03082333, 2003.
26. Watson, B.; Hohlweg, R.; Thomsen, C. Novel 1,3,8-Triazaspiro Decanones with High Affinity for Opioid Receptor Subtypes. Patent WO 99/59997, 1999.
27. Spagnola, B.; Carra, G.; Fantin, M.; Fischetti, C.; Hebbes, C.; McDonald, J.; Barnes, T. A.; Rizzi, A.; Trapella, C.; Fanton, G.; Morari, M.; Lambert, D. G.; Regoli, D.; Calo, G. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)- cis -1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5 H -benzocyclohepten-5-ol]: in vitro studies J. Pharmacol. Exp. Ther. 2007, 321, 961-967
28. Hirota, M.; Mihara, S.; Nakamura, H; Koike, H; Matsumoto, Y. Alpha Aryl or Heteroaryl Methyl Beta Piperidino Propanamide Compounds as ORL1-Receptor Antagonist. Patent WO05092858, 2005.
29. Waterhouse, R. N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents Mol. Imaging Biol. 2003, 5, 376-389
30. 125I-Tyr14-orphanin FQ with the orphanin FQ receptor: kinetics and modulation by cations and guanine nucleotides Mol. Pharmacol. 1997, 51, 816-824
31. 50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108
32. + modulation, inverse agonism, and anorectic potency of 4-phenylpiperidine opioid antagonists Eur. J. Pharmacol. 2004, 494 (2-3) 121-130
33. 35S]-guanosine- 5′- O -(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay J. Pharmacol. Exp. Ther. 1999, 289, 946-955
34. Ozaki, S.; Kawamoto, H; Itoh, Y.; Miyaji, M.; Azuma, T.; Ichikawa, D.; Nambu, H; Iguchi, T.; Iwasawa, Y.; Ohta, H In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist Eur. J. Pharmacol. 2000, 402, 45-53